Bulletin of Medical and Biological Research

[1] Guttmann-Gruber C, Hofbauer JP, Tockner B, Reichl V, Klausegger A, Hofbauer P, et al. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial. Orphanet J Rare Dis. 2021;16:473. DOI: 10.1186/s13023-021-02062-2

[2] Hou PC, Wang HT, Abhee S, Tu WT, McGrath JA, Hsu CK. Investigational treatments for epidermolysis bullosa. Am J Clin Dermatol. 2021;22:801–17. DOI: 10.1007/s40257-021-00626-3

[3] Pabón-Carrasco M, Caceres-Matos R, Roche-Campos M, Hurtado-Guapo MA, Ortiz-Romero M, Gordillo-Fernández LM, et al. Management of skin lesions in patients with epidermolysis bullosa by topical treatment: Systematic review and meta-analysis. Healthcare. 2024;12(2):261. DOI: 10.3390/healthcare12020261

[4] Bermudez NM, Warp PV, Hargis A, Yaghi M, Schachner L. Epidermolysis bullosa: A review of wound care and emerging treatments. Cur Dermatol Rep. 2024;13:123–31. DOI: 10.1007/s13671-024-00437-9

[5] Liy-Wong C, Tarango C, Pope E, Coates T, Bruckner AL, Feinstein JA, et al. Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. Orphanet J Rare Dis. 2023;18:38. DOI: 10.1186/s13023-022-02448-w

[6] Raboei E, Alabdali A, Owiwi Y, Yousef Y, Alsaggaf A, Bustanji N, et al. Overview of complications associated with epidermolysis bullosa: A multicenter retrospective clinical analysis of 152 cases. J Pediatr Surg. 2021;56(12):2392–8. DOI: 10.1016/j.jpedsurg.2021.05.023

[7] Robertson SJ, Prodinger C, Liu L, Skilbeck C, Petrof G, Martinez AE, et al. Otological complications in inversa type recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2022;47(4):717–23. DOI: 10.1111/ced.15029

[8] Yavuz Y, An I, Yazmaci B, Akkus Z, Ortac H. Evaluation of clinical and oral findings in patients with epidermolysis bullosa. Medicina. 2023;59(7):1185. DOI: 10.3390/medicina59071185

[9] Stracy M, Snitser O, Yelin I, Amer Y, Parizade M, Katz R, et al. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. Science. 2022;375(6583):889–94. DOI: 10.1126/science.abg9868

[10] Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance. Eur J Intern Med. 2022;99:7–12. DOI: 10.1016/j.ejim.2022.01.029

[11] Reimer-Taschenbrecker A, Künstner A, Hirose M, Hübner S, Gewert S, Ibrahim S, et al. Predominance of Staphylococcus correlates with wound burden and disease activity in dystrophic epidermolysis bullosa: A prospective case-control study. J Investig Dermatol. 2022;142(8):2117–27. DOI: 10.1016/j.jid.2022.01.020

[12] Azeredo J, Azevedo NF, Briandet R, Cerca N, Coenye T, Costa AR, et al. Critical review on biofilm methods. Critic Rev Microbiol. 2016;43(3):313–51. DOI: 10.1080/1040841X.2016.1208146

[13] Marvasi M, Monici M, Pantalone D, Cavalieri D. Exploitation of skin microbiota in wound healing: Perspectives during space missions. Front Bioeng Biotechnol. 2022;10:873384. DOI: 10.3389/fbioe.2022.873384

[14] White EK, Grice EA. The wound microbiome. Cold Spring Harbor Perspect Biol. 2023;15:a041218. DOI: 10.1101/cshperspect.a041218

[15] Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics – a step beyond pre- and probiotics. Nutrients. 2020;12(8):2189. DOI: 10.3390/nu12082189

[16] Rajer F, Sandegren L. The role of antibiotic resistance genes in the fitness cost of multiresistance plasmids. mBio. 2022;13(1):e03552-21. DOI: 10.1128/mbio.03552-21

[17] Seebach E, Kraus FV, Elschner T, Kubatzky KF. Staphylococci planktonic and biofilm environments differentially affect osteoclast formation. Inflammat Res. 2023;72:1465–84. DOI: 10.1007/s00011-023-01745-9

[18] Liu C, Ponsero AJ, Armstrong DG, Lipsky BA, Hurwitz BL. The dynamic wound microbiome. BMC Med. 2020;18:358. DOI: 10.1186/s12916-020-01820-6

[19] Tipton CD, Wolcott RD, Sanford NE, Miller C, Pathak G, Silzer TK, et al. Patient genetics is linked to chronic wound microbiome composition and healing. PLoS Pathog. 2020;16(6):e1008511. DOI: 10.1371/journal.ppat.1008511

[20] Suárez LJ, Garzón H, Arboleda S, Rodríguez A. Oral dysbiosis and autoimmunity: From local periodontal responses to an imbalanced systemic immunity. A review. Front Immunol. 2020;11:591255. DOI: 10.3389/fimmu.2020.591255

[21] Singh A, Amod A, Pandey P, Bose P, Pingali MS, Shivalkar S, et al. Bacterial biofilm infections, their resistance to antibiotics therapy and current treatment strategies. Biomed Mat. 2022;17(2):022003. DOI: 10.1088/1748-605x/ac50f6

[22] Kunimitsu M, Nakagami G, Kitamura A, Minematsu T, Koudounas S, Ogai K, et al. Relationship between healing status and microbial dissimilarity in wound and peri-wound skin in pressure injuries. J Tissue Viability. 2022;32(1):144–50. DOI: 10.1016/j.jtv.2022.10.006

[23] Tang Q, Xue N, Ding X, Tsai KH, Hew JJ, Jiang R, et al. Role of wound microbiome, strategies of microbiota delivery system and clinical management. Adv Drug Del Rev. 2023;192:114671. DOI: 10.1016/j.addr.2022.114671

[24] Campbell A, Bae J, Hein M, Hillis SL, Rebeck ON, Rakel BA, et al. The heterogeneous wound microbiome varies with wound care pain, dressing type, and inflammatory gene expression. Wound Repair and Regen;2024;32(6):811–25. DOI: 10.1111/wrr.13184

[25] Durand BA, Pouget C, Magnan C, Molle V, Lavigne JP, Dunyach-Remy C. Bacterial interactions in the context of chronic wound biofilm: A review. Microorganisms. 2022;10(8):1500. DOI: 10.3390/microorganisms10081500

[26] Yang Y, Huang J, Zeng A, Long X, Yu N, Wang X. The role of the skin microbiome in wound healing. Burns Trauma. 2024;12:tkad059. DOI: 10.1093/burnst/tkad059

[27] Shibata K, Ogai K, Ogura K, Urai T, Aoki M, Arisandi, D, et al. Skin physiology and its microbiome as factors associated with the recurrence of pressure injuries. Biol Res Nurs. 2021;23(1):75–81. DOI: 10.1177/1099800420941100

[28] Thaarup IC, Iversen AKS, Lichtenberg M, Bjarnsholt T, Jakobsen TH. Biofilm survival strategies in chronic wounds. Microorganisms. 2022;10(4):775. DOI: 10.3390/microorganisms10040775

[29] Harris N, Fulchand S, Nazaroff J, Li S, Tang JY. Natural history of spontaneous wound healing in recessive dystrophic epidermolysis bullosa wound types using a mobile photography application. J Investig Dermatol. 2023;143(5):S260. DOI: 10.1016/j.jid.2023.03.1534

[30] Thien CI, Bessa VR, Miotto IZ, Samorano LP, Rivitti-Machado MC, de Oliveira ZNP. Hereditary epidermolysis bullosa: Clinical-epidemiological profile of 278 patients at a tertiary hospital in São Paulo, Brazil. Braz Ann Dermatol. 2024;99(3):380–90. DOI: 10.1016/j.abd.2023.06.009

[31] Nyström A, Bruckner-Tuderman L, Kiritsi D. Dystrophic epidermolysis bullosa: Secondary disease mechanisms and disease modifiers. Front Gen. 2021;12:737272. DOI: 10.3389/fgene.2021.737272

[32] Kondo M, Takashima S, Goto H, Habe K, Natsuga K, Yamanaka K. Dominance of methicillin-resistant Staphylococcus aureus in a Japanese infant with recessive dystrophic epidermolysis bullosa. Case Rep Dermatol. 2021;13(2):278–81. DOI: 10.1159/000516354

[33] Chua C, Sethi R, Ong J, Low JH, Yew YW, Tay A, et al. Late inflammatory monocytes define circulatory immune dysregulation observed in skin microbiome-stratified atopic dermatitis. J Dermatol. 2023;112(3):158–61. DOI: 10.1016/j.jdermsci.2023.10.006

[34] Horev A, Brandwein M, Vaknin A, Motro Y, Moran-Gilad J. Temporal changes in the skin microbiome of epidermolysis bullosa patients following the application of wound dressings. J Clin Med. 2023;12(20):6435. DOI: 10.3390/jcm12206435

[35] Bar J, Sarig O, Lotan‐Pompan M, Dassa B, Miodovnik M, Weinberger A, et al. Evidence for cutaneous dysbiosis in dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2021;46(7):1223–9. DOI: 10.1111/ced.14592

[36] Has C, Hachem ME, Bučková H, Fischer P, Friedová M, Greco C, et al. Practical management of epidermolysis bullosa: Consensus clinical position statement from the European Reference Network for Rare Skin Diseases. J Eur Acad Dermatol Venereol. 2021;35(12):2349–60. DOI: 10.1111/jdv.17629

[37] Forss R, Hugman Z, Ridlington K, Radley M, Henry-Toledo E, O’Neill B. Does the application of a semiocclusive dressing alter the microflora of healthy intact skin on the foot? J Am Podiatr Med Associat. 2021;111(1):e01. DOI: 10.7547/18-141

[38] Mudrik-Zohar H, Carasso S, Gefen T, Zalmanovich A, Katzir M, Cohen Y, et al. Microbiome characterization of infected diabetic foot ulcers in association with clinical outcomes: Traditional cultures versus molecular sequencing methods. Front Cell Infect Microbiol. 2022;12:836699. DOI: 10.3389/fcimb.2022.836699

[39] Bauermeister A, Mannochio-Russo H, Costa-Lotufo LV, Jarmusch AK, Dorrestein PC. Mass spectrometry-based metabolomics in microbiome investigations. Nature Rev Microbiol. 2022;20:143–60. DOI: 10.1038/s41579-021-00621-9

[40] Hatzenpichler R, Krukenberg V, Spietz RL, Jay ZJ. Next-generation physiology approaches to study microbiome function at single cell level. Nature Rev Microbiol. 2020;18:241–56. DOI: 10.1038/s41579-020-0323-1

[41] Schmidt BM. Emerging diabetic foot ulcer microbiome analysis using cutting edge technologies. J Diabet Sci Tech. 2022;16(2):353–63. DOI: 10.1177/1932296821990097

[42] Jozic I, Tomic-Canic M. Flipping the script: Are cellular assays and wound fluids the next frontier in personalized wound care? J Investig Dermatol. 2024. DOI: 10.1016/j.jid.2024.08.007

[43] Doerfler P, Schoefmann N, Cabral G, Bauer W, Berli MC, Binder B, et al. Development of a cellular assay as a personalized model for testing chronic wound therapeutics. J Investig Dermatol. 2024. DOI: 10.1016/j.jid.2024.05.029

[44] So JY, Nazaroff J, Iwummadu CV, Harris N, Gorell ES, Fulchand S, et al. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17:377. DOI: 10.1186/s13023-022-02546-9

[45] Titeux M, Bonnet des Claustres M, Izmiryan A, Ragot H, Hovnanian A. Emerging drugs for the treatment of epidermolysis bullosa. Expert Opin Emerg Drug. 2020;25(4):467–89. DOI: 10.1080/14728214.2020.1839049

[46] Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, et al. Considerations for the use of phage therapy in clinical practice. Antimicr Agen Chemother. 2022;66:e02071–21. DOI: 10.1128/aac.02071-21

[47] Riedl J, Popp C, Eide C, Ebens C, Tolar J. Mesenchymal stromal cells in wound healing applications: Role of the secretome, targeted delivery and impact on recessive dystrophic epidermolysis bullosa treatment. Cytotherapy. 2021;23(11):961–73. DOI: 10.1016/j.jcyt.2021.06.004

[48] Pânzaru M, Caba L, Florea L, Braha EE, Gorduza EV. Epidermolysis bullosa – a different genetic approach in correlation with genetic heterogeneity. Diagnostics. 2022;12(6):1325. DOI: 10.3390/diagnostics12061325

[49] Oliver J, Mason W. Gene variation: The key to understanding pharmacogenomics and drug response variability. Fusion Multidiscipl Res. 2020;1(2):97-109.

[50] Kolimi P, Narala S, Nyavanandi D, Youssef AAA, Dudhipala N. Innovative treatment strategies to accelerate wound healing: Trajectory and recent advancements. Cells. 2022;11(15):2439. DOI: 10.3390/cells11152439

[51] Khan A, Riaz R, Ashraf S, Akilimali A. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa. Ann Med Surg. 2023;85(12):6298–301. DOI: 10.1097/ms9.0000000000001422

[52] Yerlett N, Loizou A, Bageta M, Petrof G, Martinez AE. Establishing an appropriate level of vitamin D supplementation in paediatric patients with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2022;47(7):1307–13. DOI: 10.1111/ced.15156

[53] Hou PC, del Agua N, Lwin SM, Hsu CK, McGrath JA. Innovations in the treatment of dystrophic epidermolysis bullosa (DEB): Current landscape and prospects. Therapeut Clin Risk Manag. 2023;19:455–73. DOI: 10.2147/TCRM.S386923

[54] Reimer A, Hess M, Schwieger‐Briel A, Kiritsi D, Schauer F, Schumann H, et al. Natural history of growth and anaemia in children with epidermolysis bullosa: A retrospective cohort study. Brit J Dermatol. 2020;182(6):1437–48. DOI: 10.1111/bjd.18475

[55] Santos MLD, Monteiro AC, Nascimento A, Barbosa S, Delgado A, Zamberlan P. Nutritional profile and topic management for wound healing in children with epidermolysis bullosa: What is the evidence? A systematic review. Rec Progr Nutrit. 2024;4(3). DOI: 10.21926/rpn.2403010

[56] Konop M, Rybka M, Drapała A. Keratin biomaterials in skin wound healing, an old player in modern medicine: A mini review. Pharmaceut. 2021;13(12):2029. DOI: 10.3390/pharmaceutics13122029

[57] Nguyen HM, Le TTN, Nguyen AT, Le HNT, Pham TT. Biomedical materials for wound dressing: Recent advances and applications. RSC Adv. 2023;13:5509–28. DOI: 10.1039/D2RA07673J

[58] Mirhaj M, Labbaf S, Tavakoli M, Seifalian AM. Emerging treatment strategies in wound care. Int Wound J. 2022;19(7):1934–54. DOI: 10.1111/iwj.13786

[59] Nita M, Pliszczyński J, Kosieradzki M, Fiedor P. Review of the latest methods of epidermolysis bullosa and other chronic wounds treatment including BIOOPA dressing. Dermatol Therap. 2021;11:1469–80. DOI: 10.1007/s13555-021-00578-w

[60] Sait H, Srivastava S, Saxena D. Integrated management strategies for epidermolysis bullosa: Current insights. Int J Gen Med. 2022;15:5133–44. DOI: 10.2147/IJGM.S342740